• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV SYS PED.W/SA 20 A.PRECHAMBER; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV SYS PED.W/SA 20 A.PRECHAMBER; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FV441T
Medical Device Problem Codes Break (1069); Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 06/07/2022
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a progav 2.0 (#fx410t) was implanted during a procedure performed on (b)(6) 2022 according to the complainant, the distal catheter ruptured spontaneously at the neck height.A part of the catheter drifted and got stuck in the abdominal cavity.The patient underwent a revision procedure.A new valve was placed.No patient complications were reported as a result of the revision procedure.Age: 12 years.Height: 156 centimeters (cm).Weight: 42 kilograms (kg).Gender: male.
 
Additional Manufacturer Narrative
Manufacturing site evaluation: investigation on-going.Should relevant additional information / investigation results become available, a supplemental medwatch report will be submitted.
 
Additional Manufacturer Narrative
Investigation: visual inspection: the following observations were made during the visual inspection: deposits on the pediatric prechamber, deposits in the inlet catheter, ruptured distal catheter.Measurement of surface of the housing: deformation detected: yes - measured value: -0,05 mm [tolerance (0 ± 0.02mm)] too much pressure on the valve, for example through the adjustment tool or resulting from a fall or hit to the head of the patient, can compromise the integrity of the valve.Permeability test: the test showed that the progav shunt system is permeable.Additionally, we tested the pediatric prechamber.Out test determined that the prechamber is permeable.During the tests, some particles were flushed out.Computer control test: the computer controlled test showed the opening pressure of the progav, at a reference flow rate of 20 ml/h in a horizontal position of the valve, to be 12.62 cmh2o.This is within the specified tolerance of 11 cmh2o ± 3 cmh2o.Additionally, the shuntassistant was tested according to standard procedure in the vertical position of the valve.At a fixed opening pressure of 20 cmh2o in the vertical position, a pressure of 20 cmh2o +4/-2 cmh2o is expected.The results indicated that at a reference flow of 20 ml/h in the vertical position, the shuntassistant® had a pressure of 19.21 cmh2o.This is within the specified tolerance of 20 cmh2o +4/-2 cmh2o.Adjustability test: the progav was found to be adjustable to all pressure settings.The shuntassistant is a fixed pressure valve, therefore the adjustability test is inapplicable.Braking force and brake function test: the braking force of the progav was within the specified tolerance and the brake function operated as expected.Internal inspection of product: in order to verify whether the investigated shunt system was compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, the valves are finally opened with a special tool.After dismantling of the valves, deposits were found in both valves.Results: based on our investigation results, we can determine a deformation of the outer housing of progav, a rupture of the distal catheter and deposits in both valves.The deposits had no affect to the technical properties at the time of the investigation.The cause of the deformation and the aforementioned functional impairment is not known to us at the time of the examination.Proteins in the cerebrospinal fluid can influence the function temporarily and are known side effects in hydrocephalus therapy.It might be a result of growth that the catheter has been torn off.Nevertheless, it is retrospective not possible for us to determine the exact cause of the rupture.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.From our point of view, no further regulatory actions are required.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV SYS PED.W/SA 20 A.PRECHAMBER
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key15117004
Report Number3004721439-2022-00220
Device Sequence Number5498869
Product Code JXG
UDI-Device Identifier04041906132545
UDI-Public4041906132545
Combination Product (Y/N)N
Initial Reporter CountryBR
PMA/510(K) Number
K103003
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2018
Device Explanted Year2022
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other,Foreign,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 09/29/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model NumberFV441T
Device Catalogue NumberFV441T
Device Lot NumberG52679C57043
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 06/27/2022
Supplement Date Received by Manufacturer08/30/2022
Initial Report FDA Received Date07/27/2022
Supplement Report FDA Received Date10/06/2022
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured09/03/2014
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age12 YR
Patient SexMale
Patient Weight42 KG
-
-